# A Phase 1 Study Investigating the Safety, Tolerability and Pharmacokinetics of KNX100 in Healthy Volunteers

> **NCT04901078** · PHASE1 · COMPLETED · sponsor: **Kinoxis Therapeutics Pty Ltd** · enrollment: 57 (actual)

## Conditions studied

- Healthy Volunteer Study
- Opioid-use Disorder

## Interventions

- **DRUG:** KNX100

## Key facts

- **NCT ID:** NCT04901078
- **Lead sponsor:** Kinoxis Therapeutics Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-07
- **Primary completion:** 2023-09-30
- **Final completion:** 2023-09-30
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2025-01-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04901078

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04901078, "A Phase 1 Study Investigating the Safety, Tolerability and Pharmacokinetics of KNX100 in Healthy Volunteers". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04901078. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*